CD19 and myeloid sarcoma: We suggest periodic clinical and biological assessments (including routine blood counts, immunoglobulin levels and CD19+/CD20+ B cell subtypes), at 3-months interval, to determine the optimal time to start a new DMT, balancing the need for remission of the gastrointestinal pathology with avoiding the risk of MS relapses and progression.